


MECTA

THE ONLY NEUROMODULATION COMPANY OFFERING 35 YEARS OF EVIDENCE BASED ECT DEVICES

■ **New! © Electronic Medical Record**

This MS Access™ -based, networkable Electronic Medical Record will revolutionize the data acquisition of your ECT treatments. The spECTrum alphanumeric data, physiological monitoring and patient data inputted by psychiatrists, anesthesiologists and nurses are imported into SIX permanent ECT MEDICAL RECORDS that can be saved as pdfs. These secure data transfers are seamless and create a powerful tool for the clinical psychiatrist. Paperless Medicine from MECTA!



EMR

■ **©spECTrum Ultrabrief ECT - The Standard of Care**

spECTrum (0.3) Ultrabrief ECT offers a simple and effective to use methodology based on peer-reviewed randomized double blind studies at Columbia University from the 1990s to 2003. Right unilateral (0.3) Ultrabrief six times seizure threshold ECT is equivalent in efficacy to a robust form of bilateral ECT with little sign of cognitive deficit. Only spECTrum Ultrabrief has 50% more energy at maximum and does not risk overdosing at minimum.



spECTrum 5000Q®


■ **New! Titration Tables** make safe and effective dosing easy (Columbia University research 0.3 and 0.5 msec).

■ **New! 18 Regulatory Agency Approvals** - ISO 13485:2003, EN ISO 9001 — ensuring MECTA's continued investment in safety.


■ Automatic Recordkeeping! © **RMSManager** saves time by easily storing digital pre-treatment, treatment and post-treatment data, and eliminating cumbersome transcription. Query, sort, select, add notes, export and print or store your ECT results quickly.

■ **EEG Data Analysis** – The ONLY existing patented seizure analysis indices based upon 10 years of peer-reviewed, clinical research by Duke University. Exclusively licensed to MECTA.

■ **New! The Healing Power of Electroconvulsive Therapy** by Kitty Dukakis and Larry Tye describes how ECT gave her back her life. An honest account of her decade's long struggle with severe depression and how she credits ECT with saving her life.



Patient & Family Video/DVD



■ **Patient and Family Materials! Dartmouth-Hitchcock Medical Center's** Electroconvulsive Therapy is the newest ECT Patient and Family Video/DVD available. Exclusively licensed to MECTA.

spECTrum Owners

Contact Us Today to Easily Upgrade

Your 5000 or 4000 Model:


- (0.3) msec Ultrabrief
- RMS/RMSManager
- Optical Motion Sensor
- New Handheld Electrodes
- EEG Data Analysis
- EEG Channels
- ECG Channel
- Quality Control Check



NEW!

HEALTH CANADA #1537
#62578, #62576
TUV Annex II Article 3
ISO 13485:2003
EN ISO 13485:2003
EN ISO 9001

DBS tDCS TMS and VNS
...THERE WAS ECT



REDEFINING ECT

MECTA has defined the standard of care for neuromodulation devices through evidence based research since its inception. A breakthrough in MECTA ECT research in 1973 at Oregon Health Sciences University, produced the *first and only modified, monitored, brief pulse ECT* – MECTA C, D, SR and JR devices. This has been the standard of care for thirty years and is the only neuromodulation modality providing up to an 80% response rate.¹ Controlled research at Columbia University with a spECTrum 5000Q^{®*} resulted in the newest form of ECT, *spECTrum ULTRABRIEF^{®2003} ECT* (UB RUL) which achieves cognitive effects that are dramatically minimized while maximizing efficacy.² Ongoing studies seek to eliminate all cognitive side effects and MECTA is committed to that outcome in its development of *MECTA SHAM^{®2005}* devices to conduct clinical TMS trials³ and *spECTrum* devices⁴ to achieve focality in brain stimulation.

We are proud that MECTA's innovative partnerships, with research centers worldwide participating in randomized, peer reviewed double blind studies, have resulted in optimized patient outcomes through four generations of ECT devices. Please contact MECTA for more information so that we can assist you with your clinical or research needs.

References:

- 1 The Practice of Electroconvulsive Therapy, Taskforce Report APA, 2001.
- 2 Sackeim HA et al. Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. *Brain Stimulation* 2008;2.
- 3 O'Reardon JP, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: A multisite randomized controlled trial. *Biological Psychiatry* 2007; 62:11.
- 4 Sackeim, HA. Convulsant and anticonvulsant properties of electroconvulsive therapy: towards a focal form of brain stimulation. *Clinical Neuroscience Research* 2004; 4:39-57.

*US Patent #5,755,744-US Patent #6,014,587-UK Patent #GB 2 307413 B

The Only Neuromodulation Company Offering 35 Years of Evidence Based ECT Technology

MECTA Corporation

www.mectacorp.com sales@mectacorp.com

Phone: 503-612-6780 503-612-6542

This material was copied from the NIM and may be

BEFORE...

From: Journal of ECT, Vol 28, No 4, 2012

DBS

tDCS


TMS

and

VNS

...THERE WAS

ECT



REDEFINING ECT

MECTA has defined the highest standard of excellence in the field of ECT neuromodulation devices through evidence based research since its inception. A breakthrough in MECTA ECT research in 1973 at Oregon Health Sciences University, produced the *first and only modified, monitored, brief pulse ECT* – MECTA C, D, SR and JR devices. This has been the highest standard of excellence for over thirty-five years. ECT continues to be the only neuromodulation modality providing up to an 80% response rate.¹ Controlled research at Columbia University with a spECTrum 5000Q[®]* resulted in the newest form of ECT, *spECTrum ULTRABRIEF[®]2003 ECT (UB RUL)* which achieves cognitive effects that are dramatically minimized while maximizing efficacy.² Ongoing studies seek to eliminate all cognitive side effects and MECTA is committed to that outcome in its development of *MECTA SHAM[®]2005* devices to conduct clinical TMS trials³ and *spECTrum* devices⁴ to achieve focality in brain stimulation.

We are proud that MECTA's innovative partnerships, with research centers worldwide participating in randomized, peer reviewed double blind studies, have resulted in optimized patient outcomes through four generations of ECT devices. Please contact MECTA for more information so that we can assist you with your clinical or research needs.

References:

- 1 The Practice of Electroconvulsive Therapy, Taskforce Report APA, 2001.
- 2 Sackeim HA et al. Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. *Brain Stimulation* 2008;2.
- 3 O'Reardon JP, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: A multisite randomized controlled trial. *Biological Psychiatry* 2007; 62:11.
- 4 Sackeim, HA. Convulsant and anticonvulsant properties of electroconvulsive therapy: towards a focal form of brain stimulation. *Clinical Neuroscience Research* 2004; 4:39-57.

*US Patent #5,755,744-US Patent #6,014,587-UK Patent #GB 2 307413 B Patent Pending

**WWW.MECTACORP.COM
HAS LAUNCHED!**



The Only Neuromodulation Company Offering 35 Years of Evidence Based ECT Technology

MECTA Corporation

www.mectacorp.com sales@mectacorp.com
Phone: 503-612-6780 Fax: 503-612-6542

This material was copied at the NLM and may be Subject US Copyright Laws